-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This month, the Nomura team at the University of California, Berkeley uploaded a paper on chemically induced deubiquitination in bioRxiv (Nomura DUBTAC 2021.
Drug source analysis
With a generation of PROTAC drugs entering the clinic and showing certain efficacy and safety, protein degradation is becoming an important frontier in the development of small molecule drugs.
Although DUBTAC seems to be a very close concept to PROTAC, there are still many key differences in implementation.
Some proteins are degraded to help treat diseases, but some proteins need protection.
There are many E3 and DUB, but apart from a few that have relatively high-activity ligands, it is not easy to find high-activity ligands with smaller molecular weights for both E3 and DUB.